IceCure's Cryoablation Gains Ground in Japan with Peer-Reviewed Validation
Event summary
- IceCure Medical highlights peer-reviewed study in International Journal of Surgery showing cryoablation's advantages over RFA for early-stage breast cancer.
- Study reports 99.02% recurrence-free rate from over 600 patients treated with cryoablation, compared to 98.6% for RFA.
- Terumo Corporation plans PMDA regulatory submission for ProSense® in Japan during H2 2026.
- IceCure prepares for participation in the 34th Annual Meeting of the Japanese Breast Cancer Society (JBCS) June 25-27, 2026.
The big picture
IceCure's cryoablation technology is gaining traction as a minimally invasive alternative to surgery for early-stage breast cancer, with strong clinical outcomes positioning it against established radiofrequency ablation (RFA) methods. The strategic focus on Japan, backed by Terumo Corporation's distribution network and upcoming regulatory submission, underscores the potential for significant market expansion in one of the world's largest medical device markets.
What we're watching
- Regulatory Momentum
- Whether Terumo's PMDA submission in H2 2026 will accelerate ProSense® adoption in Japan's breast cancer treatment landscape.
- Clinical Adoption
- How the peer-reviewed validation will impact physician preference shifts from RFA to cryoablation for early-stage breast cancer.
- Market Expansion
- The pace at which IceCure can leverage Japanese clinical data to support regulatory approvals in other key markets.
Related topics